Trials / Unknown
UnknownNCT04470063
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi-dose DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases-Randomized, Double-blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multi-dose DDO-3055 tablets in patients with anemia of non-dialysis chronic kidney diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DDO-3055 tablets | Multi-dose for DDO-3055 tablets |
| DRUG | Placebo | Multi-dose for Placebo |
Timeline
- Start date
- 2020-11-17
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2020-07-14
- Last updated
- 2021-10-26
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04470063. Inclusion in this directory is not an endorsement.